Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

Hypoglycemia Clinical Trial

Official title:

A Randomized, Placebo-controlled, Double-blind Trial of Multiple Ascending Doses of ZP4207 Administered to Healthy Volunteers to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ZP4207

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02390141
• Other study ID #: ZP4207-15007
• Status: Completed
• Phase: Phase 1
• First received: February 28, 2015
• Last updated: November 10, 2015
• Start date: April 2015
• Est. completion date: August 2015

Study information

• Verified date: November 2015
• Source: Zealand Pharma
• Contact: n/a
• Is FDA regulated: No
• Health authority: Germany: Federal Institute for Drugs and Medical DevicesGermany: Ethics Commission
• Study type: Interventional

Clinical Trial Summary

The trial is a single-centre, randomized, double-blind, phase 1b trial of multiple ascending doses of ZP4207 administered s.c. to healthy volunteers (HV) to evaluate the safety, tolerability, pharmakocinetic (PK) and pharmacodynamic (PD). Three cohorts of 8 subjects are planned. Within each cohort, the subjects will be randomly assigned to five repeated doses of ZP4207 or placebo in a 3:1 treatment allocation at trial site.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 2015
• Est. primary completion date: July 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 18 Years to 50 Years

Eligibility

Inclusion Criteria:

1. Signed and dated informed consent obtained before any trial-related activities. (Trial-related activities are any procedures that would not have been performed during normal management of the subject).

2. Caucasian

3. Healthy male subject.

4. Age between 18 and 50 years, both inclusive.

5. Body weight between 70 and 90 kg (both inclusive)

6. Fasting plasma glucose concentration <= 100 mg/dL.

7. Considered generally healthy upon completion of medical history, physical examination, vital signs, ECG and analysis of laboratory safety variables, as judged by the Investigator.

Exclusion Criteria:

1. Known or suspected hypersensitivity to IMP or related products.

2. Previous participation in this trial. Participation is defined as randomized.

3. Previous treatment with ZP4207.

4. Receipt of any medicinal product in clinical development within 3 months before randomization in this trial.

5. History of multiple and/or severe allergies to drugs or foods or a history of severe anaphylactic reaction.

6. Any history or presence of cancer except basal cell skin cancer or squamous cell skin cancer as judged by the Investigator.

7. Any history or presence of clinically relevant cardiovascular, pulmonary, respiratory, gastrointestinal, hepatic, renal, metabolic, endocrinological, haematological, dermatological, neurological, osteomuscular, articular, psychiatric, systemic, ocular, or infectious disease, or signs of acute illness as judged by the Investigator.

8. Any serious systemic infectious disease during four weeks prior to first dosing of the study drug, as judged by the Investigator.

9. Clinically significant abnormal values for haematology, biochemistry, coagulation, or urinalysis as judged by the Investigator.

10. Supine blood pressure at screening (after resting for at least 5 min in supine position) outside the ranges for systolic 95-140 mmHg blood pressure and for diastolic greater than 90 mmHg or symptoms and a heart rate at rest outside the range of 50-90 beats per minute (excluding white-coat hypertension; therefore, if a repeated measurement shows values within the range, the subject can be included in the trial).

11. Clinically significant abnormal standard 12-lead electrocardiogram (ECG) after 5 minutes resting in supine position at screening, as judged by the Investigator.

12. Significant history of alcoholism or drug abuse as judged by the Investigator or consuming more than 21 units of alcohol per week (one unit of alcohol equals about 250 mL of beer, one glass of wine of 120 mL, or 20 mL spirits).

13. A positive result in the alcohol and/or urine drug screen at the screening visit.

14. Smoker (defined as a subject who is smoking more than 7 cigarettes or the equivalent per week) within the last month prior to screening and who is not able or willing to refrain from smoking and use of nicotine substitute products one day before first dosing and during the treatment period.

15. Positive to the screening test for Hepatitis Bs antigen or Hepatitis C antibodies and/or a positive result to the test for HIV-1/2 antibodies or HIV-1 antigen.

16. Any medication (prescription and non-prescription drugs) within 14 days before IMP administration, with the exception of paracetamol or acetylsalicylic acid for occasional use to treat acute pain.

17. Blood donation or blood loss of more than 500 mL within the last 3 months.

18. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or co-operation.

19. Male who is sexually active and not surgically sterilized who and whose partner(s) is not using adequate contraceptive methods (adequate contraceptive measures include surgical sterilisation, hormonal intrauterine devices [coil], oral hormonal contraceptives, each in combination with spermicide-coated condoms), or who is not willing to refrain from sexual intercourse from the first dosing until 1 month after last dosing in the trial.

Study Design

Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Hypoglycemia

Intervention

Drug:
• ZP4207

• Placebo

Locations

Country	Name	City	State
Germany	Profil GmbH	Neuss

Sponsors (1)

Lead Sponsor	Collaborator
Zealand Pharma

Country where clinical trial is conducted

Germany, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants with adverse events	Number of participants with adverse events	28 days	Yes
Primary	Number of participants with adverse events	Changes or findings from baseline (normal ranges) in clinical safety laboratory assessments (including haematology, biochemistry, coagulation and urinalysis).	28 days	Yes
Primary	Number of participants with adverse events	Changes or findings from baseline in physical examination including Head, ears, eyes, nose, throat (HEENT), incl. thyroid gland; Heart, lung, chest; Abdomen; Skin and mucosae; Musculoskeletal system; Nervous system; Lymph node; Other findings)	28 days	Yes
Primary	Number of participants with adverse events	Changes or findings from baseline in vital signs (including systolic and diastolic blood pressure (mmHG) und heart rate (beats per minute), body temperature (°C), respiratory frequency (RF/min))	28 days	Yes
Primary	Number of participants with adverse events	Changes or findings from baseline in ECG Parameter (Heart rate, PQ, QRS, QT, QTcB)	28 days	Yes
Primary	Number of participants with adverse events	Findings in local tolerability by means of the following assessments: spontaneous pain; pain on palpation; itching; redness; oedema; induration/infiltration; other	28 days	Yes
Primary	Number of participants with adverse events	Immunogenicity (Anti-ZP4207 Antibodies)	28 days	Yes
Secondary	Areas under the plasma concentration curve compared between first and last dosing	Areas under the plasma concentration curve from 0 until 300min	5h	No
Secondary	Areas under the plasma concentration curve compared between first and last dosing	Areas under the plasma concentration curve from 0 until infinity	5 h	No
Secondary	Plasma concentration curve compared between first and last dosing	Maximum observed ZP4207 concentration	5 h	No
Secondary	Plasma concentration curve compared between first and last dosing	Time to maximum observed ZP4207 concentration	5 h	No
Secondary	Plasma concentration curve compared between first and last dosing	Terminal elimination rate constant of ZP4207	5 h	No
Secondary	Plasma concentration curve compared between first and last dosing	Terminal plasma elimination half-life calculated as t½=ln2/?z	5 h	No
Secondary	Plasma concentration curve compared between first and last dosing	Apparent volume of distribution of ZP4207 based on plasma concentration values, estimated during the terminal phase	5 h	No
Secondary	Pharmacokinetic endpoints compared between first and last dosing	Apparent plasma clearance rate of ZP4207 estimated during the terminal phase	5 h	No
Secondary	Pharmacokinetic endpoints compared between first and last dosing	Mean residence time for plasma ZP4207	5 h	No
Secondary	Pharmacodynamic endpoints compared between first and last dosing	Area under the plasma glucose curve from 0 until 300min	5 h	No
Secondary	Pharmacodynamic endpoints compared between first and last dosing	Maximum observed plasma glucose concentration	5 h	No
Secondary	Pharmacodynamic endpoints compared between first and last dosing	Time to maximum plasma glucose concentration	5 h	No
Secondary	Pharmacodynamic endpoints compared between first and last dosing	Delta (time to increase) of glucose of 2 mmol/	5 h	No